Sildenafil Citrate Tablet, Film Coated
Product Images NDC 51655-794

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 51655-794). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 794 54 Master Bottle Label Approval Rev A 01 22)

Label (51655 794 54 Master Bottle Label Approval Rev A 01 22)
Sildenafil is a medication presented in 15 tablets per package with a dosage of 100 mg. It contains citrate USP equivalent to 100mg of sidenafil. It is a prescription drug, so patients should follow the package insert instructions. The tablets should be stored in a container at a temperature ranging between 20°-25°C (68°-77°F). The tablets are film-coated and repackaged from 13668-188-XX by Torrent Pharma Inc. and repackaged by Northwind Pharmaceuticals in Indianapolis. The product's GTIN is 0035165794548, and the S/N is 000000000000000. The expiration date is programmed to be 00/00/0000, and the lot number should be 0000000000. Lastly, it is not advised to be kept near children.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
The text appears to be a graph showing the systolic blood pressure in mmHg at different time intervals after taking Sildenafil 100mg or placebo. The blood pressure values are shown on the y-axis and the time post-dose is shown on the x-axis. "Pre-Dose" indicates the starting point of the test, "Time post dose" indicates how long after taking the medication the blood pressure was measured. The graph shows that after taking Sildenafil, the systolic blood pressure decreased gradually over time, while the placebo group remained relatively constant.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
The text is describing a change in systolic blood pressure (SBP) in millimeters of mercury (mmHg) over time (in hours) after taking either Doxazosin alone with a placebo or Doxazosin combined with Sildenafil 25mg. It shows a graph representing the change in SBP over 7 hours post-dose.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
The text describes a chart that shows the change in SBP (Systolic Blood Pressure) expressed in mmHG (millimeters of mercury), with two different treatments named "Doxazosin + Placebo" and "Doxazosin + Sildenafil 50 mg". The chart displays data for time postdose measured in hours up to 8.000.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
The text seems to contain only a list of drug names, dosages, and a numerical chart for time after dosing. No useful description can be generated from this text.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
This text provides information on plasma concentrations of a commercial tablet at different time points post dose. However, the specifics of the tablet and the substance being tested are not available.*
FDA Label Image

Figure-6-1 (Figure 6 1)

Figure-6-1 (Figure 6 1)
This is a table with data on the percentage of patients at endpoint and baseline score. It seems to be related to a medical or clinical study, but without additional information, its purpose is not clear.*
FDA Label Image

Figure-6-2 (Figure 6 2)

Figure-6-2 (Figure 6 2)
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
This data represents the percentage of patients reporting improvement after being treated with varying doses of sildenafil citrate compared to a placebo. The data shows that the highest percentage of patients reporting improvement was in the 100mg group at 63%, followed by the 50mg group at 74%, and the 25mg group at 82%. The placebo group had the lowest percentage of patients reporting improvement at 24%. The total number of patients evaluated in this study was 463 for the placebo and 214, 391, and 380 for the 25mg, 50mg, and 100mg groups respectively.*
FDA Label Image
Torrent-logo (Torrent Logo)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.